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SUMMARY 
Leukotrienes (LT) are potent lipid mediators derived from arachidonic acid (AA) via the 
5-LO pathway [1]. First, AA is converted to 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-HPETE), which in turn is metabolized to LTA4. In the cell, 5-
LO activity depends on a crucial translocation from the soluble compartment to the 
nuclear membrane-bound 5-lipoxygenase-activating protein (FLAP) to achieve 
endogenously released AA as substrate for LT biosynthesis [2]. Although 5-LO and LT 
biosynthesis is known for more than 35 years, a role in the development of 
cardiovascular diseases (CVD), cancer, and Alzheimer`s disease besides chronic 
allergic diseases like asthma has only recently been discovered [3]. Genetic knock-out 
of FLAP as well as pharmacological inhibition precludes metabolism of AA via the 5-
LO/FLAP pathway upon stimulation [4].Therefore, FLAP displays a promising drug 
target for LT-associated diseases. 
Inspired by the therapeutic potential, BRP-7 as a novel chemotype for FLAP inhibitors 
was identified in a virtual screening approach [5]. Unlike well-established FLAP 
antagonists, the core of BRP-7 is a non-acidic benzimidazole ring, lacking typical 
pharmacophoric moieties of well-established FLAP inhibitors. The first part of this 
thesis concentrates on the pharmacological characterization of BRP-7 in vitro and in 
vivo (manuscript I). The potent inhibition of BRP-7 in intact primary human monocytes 
(IC50: 40 nM) and neutrophils (IC50: 150 nM), as well as in human whole-blood (HWB) 
(IC50: 4.8 µM) and two in vivo animal models of acute inflammation highlights the 
pharmacological potential of BRP-7 as FLAP antagonist. No significant inhibition of 
BRP-7 in cell-free assays or upon exogenous substrate supply to A23187-stimulated 
cells was observed, which is a common characteristic of FLAP inhibitors.  
Detailed knowledge about the complex regulation of 5-LO and FLAP as key enzymes 
in LT biosynthesis is incomplete, and novel innovative molecular pharmacological 
approaches are rare. Moreover, FLAP as a membrane-embedded protein devoid of 
enzymatic activity hampers the study of FLAP outside the cellular context. So far it has 
been speculated in the literature that FLAP and 5-LO co-localize at the nuclear 
membrane upon stimulation to establish the biosynthetic LTA4 complex. However, no 
distinct proof for a functional protein-protein interaction in cellulo has been given until 
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now due to insufficient experimental approaches. Consequently, putative FLAP 
inhibitors, and their influence on the LTA4-biosynthetic 5-LO/FLAP complex could not 
be properly determined. Our laboratory was the first to establish a powerful cell-based 
model to overcome these difficulties. In brief, HEK293 cells were stably transfected 
with FLAP and/or 5-LO (manuscript II). Co-expression of 5-LO and FLAP significantly 
increased cellular 5-LO activity by supporting the biosynthesis of LTA4 which was 
blocked by FLAP antagonists but not by direct 5-LO inhibitors. Moreover, 5-LO 
membrane association was strengthened in FLAP co-expressing cells. The results 
imply that FLAP not only positions AA into the active site of 5-LO but also the 
intermediate 5-HPETE to assure efficient LTA4 formation. Thus, we identified a novel 
function of FLAP, that is, support of the LTA4 synthase activity of 5-LO without marked 
effects on the 5-HETE production. Seemingly, FLAP acts as a scaffolding protein for 
the assembly of the LT-biosynthetic complex that occurs at the nuclear membrane of 
activated cells but whether 5-LO and FLAP physically interact remained elusive.  
A novel and highly specific fluorescence technique, that is, the proximity ligation assay 
(PLA) [6], yields distinct proof for a direct in situ protein-protein interaction of native 5-
LO and FLAP in HEK293 cells as well as primary human monocytes and neutrophils 
(manuscript III). For the first time, we identified a functional interaction between 5-LO 
and FLAP at a time point where 5-LO translocation, co-localization with FLAP and LT 
biosynthesis was already terminated. Pharmacological inhibition of FLAP as well as 
inhibition of AA release prevents an assembly of the 5-LO/FLAP complex without 
influencing 5-LO translocation and co-localization with FLAP. Exogenous supply of AA 
or 5-HPETE restored the interaction, supporting our hypothesis of FLAP being 
indispensable for the assembly of the LTA4-biosynthetic complex by presenting AA and 
5-HPETE as substrates to 5-LO.  
Together, this thesis supports the role of FLAP for cellular LT biosynthesis, and 
provides novel insights related to FLAP as a rather regulating protein for 5-LO activity 
than simply an “activating” one. We speculate that FLAP controls the fate of AA 
metabolism towards LTA4, and tempers the pro-inflammatory response by assembling 
a tight 5-LO/FLAP complex at the nuclear membrane to limit 5-LO activity. The results 
provide an excellent cellular model for the evaluation of putative FLAP antagonists on 
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one hand, and reveal significant insights into the functional 5-LO/FLAP interaction in 
primary human cells by PLA.  
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ZUSAMMENFASSUNG 
Die enzymatische Umwandlung von Arachidonsäure (AA) über den 5-Lipoxygenase 
(5-LO)-Weg führt zu wichtigen Entzündungsmediatoren, den Leukotrienen (LT) [1]. 
Durch regiospezifische Wasserstoffabstraktion und anschließender Oxidation wird AA 
im ersten Schritt (Dioxygenaseaktivität) zum Peroxid 5(S)-Hydroperoxy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5-HPETE) metabolisiert, um dann in einem zweiten 
Schritt (Epoxidaseaktivität) in LTA4 umgewandelt zu werden. In intakten Zellen ist für 
die zelluläre katalytische Aktivität der 5-LO eine Stimulus-induzierte Translokation aus 
dem Zytosol zu dem kernmembranständigen 5-Lipoxygenase-aktivierenden Protein 
(FLAP) essentiell [2]. Obwohl die Identität der LT sowie deren Biosynthese bereits vor 
35 Jahren aufgeklärt wurde, weiß man erst seit kurzem, dass diese Lipidmediatoren 
neben Asthma und allergischer Rhinitis auch bei Alzheimer, Krebs und Herz-Kreislauf-
Erkrankungen eine wichtige Rolle spielen. Sowohl genetischer Knock-out von FLAP in 
Mäusen als auch die pharmakologische Inhibition von FLAP als Target verhindert die 
Metabolisierung von AA zu pro-inflammatorischen LT über den 5-LO/FLAP Weg [4]. 
FLAP bietet somit vielversprechende Therapieansätze zur Behandlung LT-assoziierter 
Erkrankungen. Ein großer Vorteil der FLAP Inhibitoren ist die potente Wirksamkeit bei 
kardiovaskulären Erkrankungen, zusätzlich zu ihrem ausgeprägten Potential als 
Hemmstoffe akuter und chronischer Entzündungskrankheiten [7]. 
Auf der Suche nach innovativen und hochpotenten FLAP Antagonisten wurde im 
Rahmen dieser Arbeit erstmals ein kombiniertes Liganden- und Struktur-basiertes 
Pharmakophormodell für potentielle FLAP Inhibitoren entwickelt und BRP-7 als neue 
Leitstruktur für FLAP Antagonisten ermittelt [5]. Im Gegensatz zu etablierten FLAP 
Inhibitoren enthält BRP-7 einen Benzimidazolring als Grundstruktur, ohne die für FLAP 
Antagonisten charakteristische Säurefunktion. Der erste Teil dieser Arbeit beschäftigt 
sich mit der ausführlichen Charakterisierung der Pharmakologie von BRP-7 
(Manuskript I). Die potente Inhibition der LT-Synthese durch BRP-7 in intakten 
primären humanen Monozyten (IC50: 40 nM) und Neutrophilen (IC50: 150 nM), sowie 
dessen starke Hemmung in humanem Vollblut (IC50: 4.8 µM) als auch in vivo 
unterstreichen das hohe pharmakologische Potential von BRP-7. Wie erwartet fand 
 Zusammenfassung 
IX 
 
 
keine signifikante Hemmung der 5-LO Aktivität durch BRP-7 in zellfreien 
Untersuchungen oder nach Zugabe exogener AA zu intakten Zellen statt. 
Das Wissen um die molekulare Regulation von 5-LO und FLAP als Schlüsselenzyme 
der LT-Synthese ist jedoch lückenhaft und innovative, molekularpharmakologische 
Ansätze sind stark limitiert. Hinzu kommt, dass FLAP als kernmembranständiges 
Protein keine enzymatische Aktivität besitzt. Bislang wurde in der Literatur spekuliert, 
dass FLAP und 5-LO an der Kernmembran ko-lokalisieren um dort in orchestrierter 
Weise miteinander zu interagieren. Nachgewiesen wurde diese zelluläre Interaktion 
aufgrund unzureichender experimenteller Methodik bislang nicht. Im Rahmen dieser 
Arbeit gelang es erstmals rekombinantes FLAP und/oder 5-LO stabil in HEK293 Zellen 
zu exprimieren (Manuskript II). Die Ko-expression von 5-LO und FLAP steigerte 
signifikant die 5-LO Produktbildung ausschließlich in intakten Zellen durch eine 
gezielte Erhöhung der LTA4 Synthese, was durch FLAP Inhibitoren geblockt werden 
konnte. Weiterhin wurde die Membranassoziation der 5-LO nach Stimulation in FLAP 
exprimierenden Zellen deutlich gesteigert. Die Ergebnisse legen nahe, dass FLAP 
neben AA zusätzlich das Intermediat 5-HPETE am aktiven Zentrum der 5-LO 
positioniert. Dies stellt eine bisher unbekannte Funktion von FLAP dar.   
Obwohl die Daten darauf hindeuten, blieb die Frage nach einer direkten Protein-
Protein-Interaktion zwischen 5-LO und FLAP für den Substraterwerb und dessen 
Umsetzung zu den LT unbeantwortet. Mit der Etablierung einer hochempfindlichen und 
spezifischen fluoreszenzmikroskopischen Technik, dem Proximity Ligation Assay 
(PLA) [6], konnte erstmalig eine direkte in situ Protein-Protein-Interaktion zwischen 5-
LO und FLAP in HEK293 Zellen sowie primären humanen Monozyten und 
Neutrophilen nachgewiesen werden (Manuskript III). Während Translokation und Ko-
lokalisation mit FLAP parallel zur 5-LO Produktbildung verläuft, findet die 5-LO/FLAP 
Interaktion zeitverzögert statt. Sowohl die pharmakologische Inhibition von FLAP als 
auch die Hemmung der AA Freisetzung unterbindet eine Interaktion der beiden 
Proteine an der Kernmembran, ohne dass ein Einfluss auf das Translokationsverhalten 
der 5-LO durch die jeweiligen Inhibitoren beobachtet werden konnte. 
Interessanterweise konnte durch Zugabe exogener AA oder 5-HPETE die funktionelle 
5-LO/FLAP Interaktion wieder hergestellt werden. Die Ergebnisse unterstützen die 
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Hypothese, dass FLAP unabdinglich für die LTA4 Bildung ist, indem es das Intermediat 
5-HPETE am aktiven Zentrum der 5-LO hält. 
Zusammenfassend zeigen die neuen Erkenntnisse, dass FLAP nicht nur ein 
“aktivierendes”, sondern vielmehr ein regulierendes Protein für die 5-LO Aktivität 
darstellt. Anscheinend steuert FLAP die 5-LO Produktbildung und limitiert die pro-
inflammatorische Antwort durch Etablierung eines inaktiven 5-LO/FLAP Komplexes an 
der Kernmembran was zu einer Beeindigung der Produktbildung führt. Die Ergebnisse 
tragen dazu bei FLAP Antagonisten zukünftig eindeutig anhand des HEK293 
Zellmodels zu identifizieren und deren inhibitorisches Potential zur Ausbildung des 
LTA4-synthetisierenden 5-LO/FLAP Komplexes im PLA an Primärzellen zu 
untersuchen.  
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1. INTRODUCTION 
1.1 Eicosanoids in inflammation 
Acute inflammation is a necessary and mainly beneficial host defense process that 
goes along with redness, pain, swelling and heat, accomplished by cells of the human 
immune system to eliminate the injurious stimuli, and induce healing [8]. Although host 
defense is mostly beneficial, hypersensitive responses to allergens contribute to 
excessive activation of immune cells, leading to uncontrolled manifestation of 
autoimmune diseases and chronic inflammation. Persistent and non-resolving 
inflammation forms the basis for a diverse field of pathophysiological human diseases 
including asthma, cancer and atherosclerosis [3, 9, 10]. Besides cytokines and factors 
of the complement system, lipid mediators derived from arachidonic acid (AA) capture 
an extraordinary role in this process as inflammatory signaling molecules. The first 
committed step in the formation of these inflammatory lipid mediators is the release of 
AA from phospholipids by cytosolic phospholipase A2-α (cPLA2-α). Dioxygenation of 
AA via two mayor pathways: the cyclooxygenase (COX) [11] and the lipoxygenase (LO) 
pathway [12] leads to a group of lipid mediators called eicosanoids, including 
prostaglandins (PG), thromboxanes (TX), lipoxins (LX), and leukotrienes (LT). 
Additionally, AA is converted by the actions of the cytochrome p450 (CYP 450) 
enzymes to the anti-inflammatory epoxyeicosatrienoic acids (EETs) (Fig. 1) [13]. So 
far, two mammalian COX isofomes (COX-1 and COX-2) and six mammalian LO 
isozymes are known in the human body. Among the six human LOs, classified by their 
regio- and stereoselectivity for AA oxygenation [14], 5-Lipoxygenase (5-LO) plays an 
extraordinary role during inflammation as catalytic enzyme in LT biosynthesis [15].  
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Fig. 1: Eicosanoid metabolism. Stimulus-induced AA release from phospholipids by cPLA2-α is the 
first step in the eicosanoid cascade. AA is further metabolized by three different pathways. The COX 
pathway forms prostaglandins, thromboxanes and prostacyclin via the intermediate PGG2. All LOs (e.g. 
5-LO, 12-LO, 15-LO) synthesize H(p)ETE, depending on their regioselectivity to introduce oxygen. 5-
H(p)ETE is further metabolized by a second 5-LO reaction to LTA4, the common substrate for 
leukotrienes. LX production requires both, 15-LO (or 12-LO) and 5-LO activity. The CYP 450 pathway 
leads to the formation of EETs. 
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1.2 5-LO – key enzyme in leukotriene biosynthesis 
1.2.1 Discovery of the leukotrienes 
The term leukotriene is composed of “leuko”, attributed to their discovery in leukocytes, 
and “triene”, referring to three conjugated double bonds as common characteristics. 
More than 35 years of extensive studies have passed since their structure was first 
described. In 1976, Bengt Samuelsson, revealed the conversion of AA to 5(S)-
hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) in rabbit 
polymorphonuclear leukocytes (PMNL) [16] that is rapidly reduced to the 
corresponding alcohol 5(S)-hydroxyeicosatetraenoic acid (5-HETE). Three years later, 
5-H(p)ETE and LTB4 were identified in human PMNL [17]. The latter is derived from 
LTA4, an unstable epoxide that is formed from 5-HPETE by 5-LO [18]. Later, the "Slow-
reacting substances of anaphylaxis" (SRS-A, described already in 1938) [19] were 
identified as a mixture of lipid mediators containing LTC4, LTD4 and LTE4, collectively 
termed as cysteinyl-LTs (cys-LTs), formed by LTC4 synthase (LTC4-S) from LTA4 [15]. 
 
1.2.2 Leukotrienes in human diseases 
In general, LTs are known for their actions during acute inflammation and asthma 
bronchiale [3]. While LTB4 is a potent chemokine that evokes chemotaxis and active 
movement of inflammatory cells upon stimulation, cys-LTs exhibit powerful 
bronchoconstrictive effects [20]. During the last three decades the list of LT-related 
diseases expanded, and chronic inflammation has been shown to be a risk factor for 
cardiovascular diseases (CVD) as well as for the development of cancer [9, 21]. 
Especially in the pathophysiology of atherosclerosis, a link between inflammation and 
the immune system is well accepted. Atherosclerotic plaques contain pro-inflammatory 
substances formed via the 5-LO pathway, and elevated levels of 5-LO products in 
atherosclerotic lesion promote plaque instability [21]. Moreover, increased expression 
levels of 5-LO, LTB4 receptors and cys-LT1 receptor were observed in certain types of 
cancer [9], and 5-LO products released by cancer cells as well as invading cells 
contribute to survival and growth of the tumor [22]. On the other hand, transcellular 
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biosynthesis involving 5-LO and other LO activities provide mediators that contribute 
to resolution. The production of anti-inflammatory mediators like LXs or resolvins 
require for instances, the combined actions of 5-LO and 15-LO (or 12-LO) for 
successive AA oxygenation [23, 24]. 
 
1.2.3  Catalytic activity of 5-LO 
5-LO, the key enzyme in LT biosynthesis, is a non-heme iron-containing dioxygenase 
that catalyzes the conversion of AA to LTA4 in a two-step reaction [18]. The oxidation 
of the iron initiates the 5-LO catalytic cycle [25]. The inactive ferrous (Fe2+) is oxidized 
to the active ferric (Fe3+) form by lipid hydroperoxides (LOOH) [26]. Fe3+ is now 
coordinated by a hydroxide ion instead of water, enabling AA to enter the catalytic 
cavity [27]. The first AA-converting step is common for all other LOs. A hydrogen is 
stereospecifically abstracted to form a radical that undergoes a rearrangement for 
oxygen insertion. 5-LO abstracts the pro-S-hydrogen of carbon (C)-7 with a radical 
rearrangement to C-5, generating a trans double bond. Subsequently, oxygen is 
introduced at C-5 in an antarafacial manner to produce 5-HPETE. The intermediate 5-
HPETE can either be non-enzymatically reduced by peroxidases to the corresponding 
alcohol 5-HETE or converted into the unstable epoxide LTA4 by 5-LO in a second 
catalytic step. Therefor, the enzyme abstracts the pro-R hydrogen at C-10 with radical 
migration to C-6. The radical combines with the hydroperoxy group at C-5, followed by 
dehydration to yield LTA4 [12, 28] (Fig. 2.). Among all LOs, this two-step concerted 
reaction is unique for 5-LO, and no other LO than 5-LO comprises a so-called LTA4 
synthase activity. The ratio of 5-H(p)ETE to LTA4 depends on multiple regulating factors 
for 5-LO activity, assay conditions as well as cellular compartmentalization [29, 30]. 5-
H(p)ETE production is favoured at high substrate and enzyme concentrations, for 
example if cells or purified 5-LO is stimulated with high concentrations of exogenous 
AA [31]. LTA4 formation however, is prompted in intact cells by membrane binding [32] 
and association of 5-LO with its scaffolds coactosin-like protein (CLP) and 5-
lipoxygenase-activating protein (FLAP) [2, 33]. Especially the induced nuclear 
membrane binding of 5-LO via its proposed membrane anchor FLAP promotes LTA4 
formation [34]. 
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Fig. 2: 5-LO catalytic pathway. (Left) Schematic representation of cellular LT biosynthesis at the 
nuclear membrane upon stimulation. (Right) Metabolites and key enzymes of the 5-LO pathway. 
 
1.2.4  Structure and function relationship 
Purification and cDNA cloning of human 5-LO from various leukocytes revealed a 
soluble monomeric enzyme of 672 or 673 amino acids (aa) with a molecular weight of 
72 to 80 kDa [35]. The first crystallized mammalian LO structure was the rabbit 
reticulocyte 15-LO in 1997 [36]. Many crystal structures of the LO family followed, but 
despite intensive attempts to crystallize human 5-LO for decades, researchers failed 
due to destabilizing protein sequences. The only available structure was a 15-LO 
crystal-based model, suggesting an N-terminal β-barrel regulatory domain and a C-
terminal iron-containing catalytic domain for 5-LO. Finally in 2011, the first crystal 
structure of a so-called “stable-5-LO” was revealed (Fig. 3). Several mutations and 
deletions were applied to stabilize the protein for crystallization: replacement of three 
lysines (Lys563-565) with Glu-Gln-Leu from coral 8(R)-LO, deletion of putative Ca2+-
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binding sites and membrane insertion residues (Δ40-44, Trp13Glu, Phe14His, Trp75Gly, 
Leu76Ser, Cys240Ala, and Cys561Ala) [27].  
Fig. 3: Structure of “stable 5-LO”. (Left) The cartoon rendering of the crystal structure of 5-LO (Protein 
Data Bank accession code, 3ORY) with the N-terminal C2-like domain (blue) and C-terminal catalytic 
domain (palegreen) containing the active site (lightblue) with the non-heme iron (yellow). (Right) Detail 
of the arched α-2 helix that closes the entry to the catalytic cavity. The potential AA entrance site is 
shown in stick rendering: Phe177 and Tyr181 (pink; “FY cork”), their respective counterparts Ala603 and 
Ala606 (blue) and stabilizingTrp599 (blue). 
 
1.2.4.1 N-terminal regulatory C2-like domain 
The smaller N-terminal C2-like domain (residues 1-120) is a mostly negatively charged 
β-barrel domain, containing several regulatory factor binding sites e.g. for calcium 
(Ca2+), phosphatidyl choline (PC), and CLP [37-39]. Two four-stranded antiparallel β-
sheets define the β-sandwich of the C2-like domain. Binding assays with radioactive-
labeled Ca2+ suggest three important residues in loop 2 (Asn43, Asp44, and Glu46) to be 
responsible for 5-LO activation via Ca2+ [37]. Ca2+-binding to the C2-like domain is 
suggested to target 5-LO to the membranes [40]. It has been reported that 5-LO shows 
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high selectivity for PC and that this binding is Ca2+-mediated by exposing three 
tryptophans (Trp13, Trp75, and Trp102) to the surface [41]. Especially Trp75 has been 
shown to insert deep into the lipid bilayer. Since AA-esterified PC lipids are 
predominantly found in the nuclear membrane of cells [32], the Ca2+-mediated 
preference for PC-binding is believed to initiate 5-LO translocation from the cytosol to 
the nuclear membrane. Indeed, a truncated GFP-tagged N-terminal domain construct, 
but not the respective C-terminal part, was sufficient for 5-LO translocation to the 
nuclear membrane [42]. This ability was solely observed for the N-terminal domain of 
5-LO, and not for other LOs [42]. In line with these findings, human CLP was shown to 
bind and stabilize 5-LO in vitro via binding to the C-2 like domain. Especially Trp102 
appears to be crucial for the association with CLP [43]. GST pull-down assays as well 
as yeast two-hybrid binding assays revealed human dicer as another interaction 
partner of 5-LO. Dicer has been described to bind to the N-terminal β-barrel domain, 
involving the three tryptophans mentioned above, and to increase 5-LO activity in vitro 
[44].  
 
1.2.4.2  C-terminal catalytic domain 
In contrast to the β-barrel sheets containing N-terminal domain, the C-terminal catalytic 
domain (residues 121-673) is mainly composed of α-helices, sheltering the non-heme 
catalytic iron in the center. An aspartate (Asn554), three conserved histidines (His367, 
His372, and His550) together with the C-terminal carboxyl end of Ile673 define the active 
site and coordinate the iron [27]. A water molecule resides at the sixth position. As 
described for many other non-heme iron containing enzymes, two histidines and one 
C-terminal carboxyl group are pivotal to anchor the iron. Mutational studies of 5-LOs 
active site suggest that His372, His550, and Ile673 form that triad, while His367 and Asn554 
act as exchangeable ligands of the active site iron [45]. As described for soybean LO, 
an arched helix is covering access to the catalytic center [46], containing the highly 
conserved Leu414. Together with Leu420 and Phe421, this arched helix shields the 
catalytic site [27]. These residues have been described before for other LOs to be 
pivotal for substrate positioning and oxygen access.  
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The most unique part of the 5-LO structure is the configuration of the α-2 helix. While 
other LOs (e.g. human 15-LO-2 [47] and coral 8-LO [48]) contain a straight oriented 
six to seven turn long α-2 helix, the α-2 helix in 5-LO is a broken helix with three-turns, 
flanked by extended loops and a ~ 45° rotamer shift. Especially the position and 
orientation of the two bulky amino acids Phe177 and Tyr181 appear to close the entrance 
of AA to 5-LO`s active site, for which reason these two residues are often referred to 
as the “FY cork” [27]. Their bulky side chains are oriented towards the proposed 
substrate access channel with two alanines (Ala603 and Ala606) across from them. The 
small side chains prompt the “FY cork” to point inwards and close the cavity, while 
Trp599 stabilizes the FY cork from the opposite side [27]. Eventually, product specificity 
among all AA-metabolizing enzymes is determined by two facts: (I) cavity depth, 
limiting how deep AA can slide into the cavity for attack, and (II) whether the substrate 
enters head (carboxyl) or tail (hydrocarbon) first. For 5-LO a head-first entry of AA is 
predicted [49]. A tail-first entry is limited by cavity depth (His600) and would produce R 
stereochemistry instead of 5(S)-H(p)ETE. Taken together, the unique assembly around 
the “FY cork” defines the entrance of AA to the active site of 5-LO and controls regio- 
and stereoselective oxygenation of AA. While Phe177 is an invariant amino acid in other 
LO catalytic cavities, Tyr181 is specific for 5-LO. Instead of the bulky hydrophilic 
tyrosine, small hydrophobic aa reside at this position in other LO structures (Fig. 4). 
The “corked” cavity of 5-LO causes a lot of speculations about how AA can enter the 
active site.  
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Fig. 4: Partial sequence alignment of 5(S)-LO and homologue position in other human LOs (Top) 
Residues defining the AA entrance site are surrounded in red (Phe177 and Tyr181 in 5-LO; “FY cork”). 
(Middle) Counterparts of the FY cork are surrounded in blue (Ala603 and Ala606 in 5-LO). (Bottom) Highly 
conserved histidines (His367 and His372 in 5-LO) coordinate the catalytic iron (green boxes). 
 
1.2.5  Enzyme activity regulation 
Among the AA-metabolizing pathways, the 5-LO pathway is probably the most complex 
regulated one. As described in detail below, 5-LO catalysis is strongly controlled by an 
accurate and fine-tuned machinery involving cofactors, second messengers, signaling 
kinase pathways, scaffolding proteins, redox status, compartmentalization, gender 
specificity, and self-inactivation [50]. 
 
5(S)-LO_J03571  175 V D F V L N Y S K A M 
12(R)-LO_AF038461  207 A S F F V R L G P M A 
12(S)-LO_M58704  171 L D F E W T L K A G A 
15(S)-LO-1_M2389  171 V D F E V S L A K G L 
15(S)-LO-2_U78294  181 A N F Y L Q A G S A F 
 
5(S)-LO_J03571  603 A V W A L S Q F Q E N 
12(R)-LO_AF038461  630 V L W T L S R E P D D 
12(S)-LO_M58704  592 I S W H L S R R Q P D 
15(S)-LO-1_M2389  591 I T W Q L G R R Q P V 
15(S)-LO-2_U78294  605 A L W L L S K E P G D 
 
5(S)-LO_J03571  365 I T H L L R T H L V S 
12(R)-LO_AF038461  395 I A H L L E T H L I A 
12(S)-LO_M58704  357 Q Y H L L N T H L V A 
15(S)-LO-1_M2389  357 Q S H L L R G H L M A 
15(S)-LO-2_U78294  370 L T H L L H S H L L P 
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1.2.5.1 Calcium, PC, and CLP 
The second messenger Ca2+ was one of the first described modulating factors for LT 
biosynthesis [17]. Stimulation with Ca-ionophore (A23187) increases the permeability 
for Ca2+ ions, leading to an influx across the plasma membrane lipid bilayer into the 
cytosol. Half-maximal activity of purified 5-LO is obtained upon 1 - 2 µM, and full activity 
upon 4 – 10 µM Ca2+, while lower concentrations (200 nM) are sufficient in cellulo [51]. 
Ca2+-binding is needed for both catalytic activities of 5-LO [52]. Only slight 5-LO activity 
was demonstrated without Ca2+ addition under cell-free conditions [53]. Equilibrium 
dialysis together with gel filtration analysis revealed reversible binding of Ca2+ to 5-LO 
with a Kd of ~ 6 µM, and a stoichiometry of two Ca2+ per protein [54]. Recently, a third 
binding motif was suggested by the crystal structure of 5-LO [27]. Overall, enzyme 
activation via Ca2+ is characterized by a shorter lag phase, higher Vmax, and decreased 
KS for AA [53]. Ca2+-binding modifies substrate accessibility as well as substrate turn-
over. However, at high substrate concentrations (~ 40 µM AA), Ca2+ becomes 
redundant for purified 5-LO activity and crude cell homogenate preparations [55].  
Ca2+ in general has been shown to bind to C2-like domains of various proteins, and 
mediates their membrane association. Indeed, mutational studies of the isolated His-
tagged N-terminal C2-like domain of 5-LO verified specific binding sites for Ca2+ in loop 
2 (Asn43, Asp44, and Glu46) [37] (see 1.2.3.1). Ca2+ activation in vitro was improved by 
coincubation with cellular membrane fractions from leukocytes that were replaceable 
by lipid vesicles containing PC [52, 56]. Hence, Ca2+-binding stimulates both 5-LO 
activity as well as membrane association, illustrating the complex regulatory 
mechanism of this second messenger. The positively charged ion is believed to 
neutralize the negatively charged aa of the N-terminal domain of 5-LO for an improved 
membrane association. In this context, three tryptophanes (Trp13, Trp75, Trp102) were 
proposed to fulfill this function [41]. The preference of 5-LO for Ca2+-induced PC-
binding is believed to target cytosolic 5-LO to the AA-enriched nuclear membrane [38, 
41]. Hence, the membrane association stabilizes both, 5-LO structure and activity. 
However, weak binding of 5-LO to PC vesicles in vitro was also shown in the absence 
of Ca2+ but without enzymatic 5-LO activity, implying that membrane binding alone is 
not sufficient for LT biosynthesis [38].  
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Besides cell membranes, the 16 kDa protein CLP was shown to function as a scaffold 
for 5-LO activity in vitro and in vivo [33]. It belongs to the actin-depolymerizing 
factor/cofilin family, resembling Dictyostelium discoideum coactosin that is known to 
bind F-actin. In a yeast two-hybrid screening the protein was identified as novel 5-LO 
interaction partner [57]. The binding stoichiometry of CLP to 5-LO is 1:1, while the 
binding of CLP to F-actin is 1:2. NMR structure analysis combined with site-directed 
mutagenesis revealed different residues for the binding of CLP to 5-LO (Lys131) and F-
actin (Lys75). Although both residues are exposed on the surface in proximity to each 
other, no ternary complex has been observed so far. Instead, a competitive binding 
pattern of 5-LO and F-actin to CLP was demonstrated [58]. Co-immunoprecipitation 
experiments using epitope-tagged 5-LO and CLP in transiently transfected human 
embryonic kidney (HEK)293 cells confirmed CLP as 5-LO-binding protein in intact 
cells, supporting its relevance in vivo [43]. 5-LO was shown to migrate to the nuclear 
membrane from the cytosol in complex with CLP upon cell activation [33, 59], implying 
that the 5-LO/CLP association is permanent. The 5-LO/CLP association was shown to 
stabilize 5-LO structure and activity likewise since CLP prevented 5-LO from non-
turnover self-inactivation in vitro [39]. Although the binding of CLP and 5-LO is Ca2+-
independent, no 5-LO activity was observed in vitro without Ca2+ addition, despite the 
presence of CLP. Thus, a similar mechanism for the support of 5-LO activity is 
suggested for CLP as discussed above for PC-binding [38]. Interestingly, in the 
absence of PC vesicles CLP primarily improved 5-H(p)ETE formation, whereas co-
incubations with PC and CLP increased LTA4 formation 3- to 5-fold [33]. As mentioned 
above, three tryptophanes (Trp13, Trp75, Trp102) in the C2-like domain of 5-LO are 
important for the association with PC [41]. Thus, their relevance regarding the 5-
LO/CLP interaction was examined. While Trp75 is mainly important for membrane 
insertion and plays a central role in 5-LO membrane-association, Trp102 appears to be 
essential for the binding to CLP [39]. Site-directed mutagenesis of this residue to 
alanine prevented CLP-binding as well as CLP-mediated activity support and structure 
stabilization. Computer-based docking models however, suggest another binding 
mode for CLP to 5-LO since Trp102 is not exposed to the surface, and located deep in 
an interdomain cleft. Instead, Trp102 might interact with Arg165 of 5-LO which in turn 
binds to Lys131 in CLP via a hydrogen bond [39].  
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1.2.5.2 ATP stimulation 
Among all LOs, 5-LO is the only one capable to bind ATP. The nucleotide has been 
shown to stimulate the catalytic activity of 5-LO in vitro [60]. ATP at 0.1 - 2 mM is 
sufficient to increase 5-LO activity 2- to 6-fold in a Ca2+-dependent manner with a Kd 
of 31 µM [53]. Besides ATP, other adenosine nucleotides (ATP > ADP > AMP) show 
similar stimulatory effects without ATP hydrolysis being involved [60, 61]. 5-LO binds 
to ATP-sepharose which is a routinely used purification method for the protein [62]. The 
ATP analog 2-azido-ATP covalently modified 5-LO at Trp75 and Trp201, suggesting a 
role of the two aa or in proximity located residues in ATP-binding [62]. While Trp75 is 
located in the N-terminal domain, Trp201 resides in the catalytic domain. Stoichiometry 
analysis however, propose a 1:1 complex of 5-LO and ATP with homodimers of 5-LO 
in a head to tail confirmation to bring the two proposed ATP-binding motifs in proximity 
[63]. Subsequent site-directed mutagenesis of these residues however, did not 
influence 5-LO-binding to ATP-sepharose [64], and a truncated construct, lacking the 
N-terminal domain of 5-LO harbouring Trp75, could still be stimulated by ATP [65]. 
Recently, indirubins were found to interfere with ATP binding to 5-LO, and these 
compounds effectively inhibited 5-LO product synthesis in an ATP-competitive manner 
[66]. 
 
1.2.5.3 Lipid hydroperoxides  
The initial step of 5-LO catalysis is the oxidation of Fe2+ into Fe3+, yielding the active 
form of the enzyme, accomplished by LOOHs [67]. 5-LO catalysis shows a 
characteristic lag phase after the addition of AA to purified 5-LO or crude cell lysates. 
The addition of various hydroperoxides like 5-HPETE, 12-HPETE, 15-HPETE or 13-
HPODE reduce this lag phase [68]. Conditions promoting lipid peroxidation e.g. the 
formation of reactive oxygen species (ROS) by phorbol 12-myristate 13-acetate (PMA), 
depletion of glutathione (GSH), addition of peroxides (H2O2) or inhibitors of glutathione 
peroxidase (GPx) enzymes are beneficial for 5-LO activity [69]. Besides converting the 
iron into its active oxidized form, an increased peroxide tone upon oxidative stress 
might also activate 5-LO via phosphorylation, since oxidative stress was shown to 
induce the activation of p38 mitogen-activated protein kinase (MAPK) [61]. 
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1.2.5.4 Phosphorylation 
Phosphorylation plays a pivotal role in cell activation and turns protein functions on and 
off by altering their enzymatic activity and regulatory properties. Two key enzymes of 
the LT pathway 5-LO and cPLA2-α are activated via phosphorylation, which 
significantly impacts their cellular activity and subcellular compartmentalization (see 
also 1.4) [70]. Extracellular signals induce phosphorylation that are able to elevate 
intracellular Ca2+ levels [71, 72].Thus, both mechanism are coordinated for maximal 
cell response during inflammation. Several phosphorylation motifs have been identified 
for 5-LO. In detail, three serine residues are phosphorylated by different protein 
kinases (Fig. 5). Ser271 is the target of p38 MAPK-activated protein kinase (MAPKAPK) 
2/3, Ser663 of extracellular signal-regulated kinase 2 (ERK2), and Ser523 is activated by 
protein kinase A (PKA) [30]. First evidence for phosphorylated 5-LO was found in 
A23187-stimulated HL-60 cells, indicating that 5-LO activity and translocation is 
influenced by phosphorylation [73]. In brief, activated p38 MAPK phosphorylates and 
activates MAPKAPK 2/3 which phosphorylates 5-LO [73]. This can be blocked by the 
p38 MAPK inhibitor SB203580 [74]. In-gel migration assays combined with site-
directed mutagenesis identified Ser271 as p38 MAPK-regulated phosphorylation site of 
5-LO in vitro [72]. Interestingly, cell stress-induced 5-LO activation is Ca2+-independent 
and offers opportunities to control 5-LO activity by phosphorylation [61] that is 
enhanced by polyunsaturated fatty acids like AA [74].  
MAP kinase ERK2, was shown to phosphorylate Ser663 in vitro which can be prevented 
by the specific ERK activation inhibitor U0126 [75]. Although the stimulatory effect of 
ERK-mediated 5-LO phosphorylation is poor, exogenous substrate supply promotes 5-
LO phosphorylation in a concentration-dependent manner as seen for p38 MAPK. It 
appears that dual phosphorylation at Ser271 and Ser663 occurs coordinated to enhance 
cellular 5-LO activity [75]. Since saturated fatty acids failed to support 5-LO activity in 
vivo, phosphorylation might only take place if free AA is available upon activation [75]. 
Like p38 MAPK-induced 5-LO phosphorylation, ERK2 activity was sufficient to 
increase 5-LO product formation and induce translocation in PMA-primed cells in the 
absence of Ca2+ mobilizing agents [71]. Of interest, p38 MAPK-regulated MK 2/3 or 
ERK2-mediated phosphorylation did not influence the activity of purified 5-LO, 
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suggesting a rather modulating role for the phosphorylation for 5-LO translocation and 
interactions in cellulo [76]. 
The third phosphorylation site of 5-LO is Ser523, which is phosphorylated by the cAMP-
dependent PKA [77]. Specific 5-LO phosphorylation by PKA activators or incubation 
with a phosphomimetic glutamate derivative reduced LT biosynthesis in cell-free 
preparations as well as transiently transfected mouse NIH-3T3 fibroblasts, and 
impaired 5-LO translocation in human neutrophils [77, 78]. Site-directed mutagenesis 
of Ser523 to alanine prevented 5-LO inhibition, and restored activity [77]. PKA-mediated 
phosphorylation of 5-LO was inhibited by exogenous supply of polyunsaturated fatty 
acids such as AA in neutrophils, leading to 5-LO activation and translocation to the 
nuclear membrane [79]. Note that Ser523 is located in proximity to the nuclear 
localization sequence (NLS) of 5-LO for which reason the phosphorylation of Ser523 
reduced nuclear import of 5-LO, leading to an accumulation of 5-LO in the cytosol that 
was shown to reduce LT biosynthesis [80]. In this context, an allosteric regulation of 
phosphorylated Ser523 is thought to be involved in the control of 5-LO catalysis [77].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Concerted cellular activation of 5-LO. Depending on stimulus and cell-type, 5-LO is regulated 
by Ca2+-binding and/or phosphorylation. p38 MAPK-regulated MK 2/3 phosphorylates Ser271, Ser663 is 
the target of ERK2, and Ser523 is phosphorylated by PKA.  
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1.2.5.5 Sex specificity 
Besides their effects on sexual differentiation and reproduction, sex hormones have an 
impact on the human immune system. While estrogen is associated with pro-
inflammatory events, testosterone seems to act anti-inflammatory [81]. Especially, LT-
related diseases are more prominent in females. Recently, 5α-dihydrotestosterone (5α-
DHT) was shown to up-regulate ERK2-mediated phosphorylation in male neutrophils 
that caused initial perinuclear localization of 5-LO in resting cells, which is believed to 
reduce 5-LO activity in male neutrophils upon stimulation [82]. Besides male 
neutrophils, reduced levels of 5-LO products were also observed in male monocytes 
and human whole blood [83]. In monocytes however, the translocation pattern of 5-LO 
was marginal affected by androgens. Here, ERK2 activation reduced phospholipase D 
(PLD) activity which could be restored by exogenous supply of diacylglycerol (DAG) 
[83]. The gender differences observed in vitro were confirmed in vivo in the zymosan-
induced peritonitis model with male and female mice [84]. Furthermore, female mice 
showed higher mortality rates than male mice in a mouse model resembling human 
systemic lupus erythematosus (MRL-lpr/lpr), and the testosterone-mediated beneficial 
effect was abolished upon 5-LO gene knock-out [85]. The improved knowledge about 
gender bias-related differences in 5-LO activity may contribute to understand and 
explain the predisposition of females for LT-associated diseases. 
 
1.2.5.6 5-LO self-inactivation 
Two mechanism contribute to 5-LO self-inactivation, non-turnover-dependent structure 
instability (see also 1.2.4) and turnover-based suicide inactivation. Compared to other 
LOs, 5-LO is a fragile enzyme, a property that may be necessary to temper the pro-
inflammatory response. Purified 5-LO, for example, has a half-life of 24 h at 2 °C [86]. 
Non-turnover-dependent 5-LO inactivation involves a reaction of the central iron with 
hydroperoxides, resulting in ROS [51]. In this context, reducing agents like dithiothreitol 
(DTT) or GSH were shown to stabilize 5-LO and prolong 5-LO activity [87]. In addition, 
CLP acts as a stabilizing scaffold for 5-LO structure and activity by preventing non-
turnover based inactivation [39]. Another mechanism is 5-LO turnover-based suicide 
inactivation that occurs during 5-LO catalysis. If purified 5-LO is treated with Ca2+, 
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substrate, and PC vesicles in air-saturated buffer its half-life is reduced to ~ 30 sec. 
The rate of inactivation is predominantly dependent on substrate accessibility and 
concentration [88]. Both 5-LO products 5-HPETE and LTA4 are highly reactive 
substances that were shown to inactivate the enzyme irretrievable [89, 90]. Despite 
the fact that 5-LO is a fragile enzyme due to turnover and non-turnover inactivation, 
pro-inflammatory LT biosynthesis still occurs, and nanomolar concentrations are 
sufficient for further metabolism by downstream enzymes. 
 
1.3 5-Lipoxygenase-Activating Protein (FLAP) 
1.3.1  Discovery of FLAP and inhibition 
In 1989, scientists at Merck-Frosst discovered that the indole-class inhibitor MK886 
potently suppresses in cellulo LT biosynthesis without affecting 5-LO or cPLA2-α [91]. 
Scientists at Bayer identified a quinolone-type inhibitor (BAY X-1005) with similar 
activity [92]. Both compounds potently inhibit LT formation in intact cells after 
stimulation (e.g. with A23187) but lose their efficacy in cell homogenates or in studies 
with purified 5-LO. Dixon et al. cloned and identified the MK886-binding protein as a 
determinant for LT-biosynthesis in intact cells and termed it “Five-lipoxygenase-
activating protein” or short FLAP [2]. FLAP is a 18 kDa nuclear membrane-embedded 
protein that is believed to transfer endogenously released AA to 5-LO for metabolism 
[4]. Further drug developments resulted in indole-quinolone hybrids as MK591 [93]. 
Site-directed mutagenesis of FLAP combined with MK591-radioligand binding studies 
determined the inhibitor binding site, and suggest a partially overlapping binding site 
with AA [94, 95]. For all three compounds phase I and phase II clinical data in the 
treatment of asthma are available. However, neither one reached phase III clinical 
studies, for unknown reasons [96-98]. Recently, scientists at GlaxoSmithKline 
presented a novel FLAP inhibitor (GSK2190915), similar in structure to the compounds 
mentioned above (see Fig. 6). GSK2190915 successfully completed phase II clinical 
studies and entered phase III with promising perspectives to become the first FLAP 
inhibitor on the market for the treatment of chronic asthma [99]. Besides their potency 
in chronic allergic and respiratory diseases, animal studies as well as genetic knock-
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out experiments propose an emerging role for FLAP inhibitors in atherosclerosis, 
myocardial infarction, and stroke. MK886 for example was shown to prevent plaque 
formation and even stabilized those in a mouse atherosclerosis model [100, 101]. 
Additionally, variants of the FLAP gene (ALOX5AP) were shown to be a risk factor for 
heart attacks or stroke, and high levels of LTs are one of the determinants for the 
developing of CVD [102, 103]. To sum up, FLAP inhibitors were reported to decrease 
LTB4, myeloperoxidase (MPO), and systemic C-reactive protein (CRP) levels [104]. 
Thus, the widespread application and therapeutic potential of FLAP inhibitors is 
enormous. 
 
Fig. 6: Chemical structures of FLAP inhibitors. Despite high efficacy in early asthma trials (phase I 
and II), the first three compounds failed to enter the drug market but GSK2190915 (left) is a promising 
compound with high efficacy in phase III clinical studies. 
 
1.3.2  Structural properties of FLAP 
Due to sequence homology and structural properties, FLAP is a member of the 
membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) 
superfamily [105]. Within this family FLAP appears to resemble a subclass. The protein 
does not possess any enzymatic activity or a glutathione binding site, unlike the other 
MAPEGs that either conjugate GSH to their substrate or metabolize GSH during their 
catalytic cycle. Among all MAPEGs, FLAP and LTC4S share the highest overall 
sequence identity with 31%. [105]. Both proteins form functional trimers with four 
transmembrane domains spanning the nuclear membrane, which are nearly 
superimposable [4]. In 2007, the three-dimensional structure of human FLAP was 
solved at 4.0 Å resolution in complex with MK591 [100]. Each FLAP monomer consists 
of four transmembrane spanning helices, connected by two cytosolic loops and one 
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lumenal loop. Both the N- and the C-termini are located in the perinuclear space. The 
flattened cytosolic top together with the pointed luminal base determine FLAP`s 
cylindric shape. The MK591-binding site is located deep in a groove on the membrane-
embedded surface between helices of neighboring protomers (Fig. 7). In detail, MK591 
forms van der Waals interactions with Val20, Val21, Gly24, Phe25, and Ala27 from helix 
α1; Tyr112 and Ile113 from cytosolic loop C2; Ala63 from helix α2; and Ile119, Leu120, and 
with Phe123 from helix α4 of the adjacent monomer. Three MK591 molecules bind to 
one FLAP trimer, resulting in a stoichiometry of 1:1. [100]. Sequence alignment of 
various FLAP species revealed highly conserved residues in two cytosolic loops, 
connecting helix α1 to α2, and helix α3 with α4. Thus, these surface loops might be 
promising candidates to interact with 5-LO. The deep inhibitor-binding groove is 
consistent with a hypothesis about lateral diffusion of AA molecules through the lipid 
bilayer, and might explain how FLAP inhibitors function as competitive inhibitors for 
AA-binding. Subsequent AA-binding to FLAP is believed to induce a conformational 
change of FLAP, especially of helix α2 [100]. The inhibitor binding stoichiometry 
suggests a similar stoichiometry for AA, resulting in a 1:1 complex of one FLAP trimer 
with one 5-LO monomer and three AA molecules. Interestingly, a similar hidden binding 
pocket for LTA4 is described for the structurally-related LTC4S. Thus, a selective lateral 
transfer of LTA4 from FLAP to LTC4S within the perinuclear region is also conceivable, 
and a complex of FLAP and LTC4S is likely to be formed in order to produce LTC4 [106] 
Fig. 7: Inhibitor-bound 5-Lipoxygenase-
Activating Protein (FLAP). Cartoon 
representation of human trimeric FLAP with 
MK591 (Protein Data Bank accession code, 
2Q7M). Monomers colored in yellow, grey, 
and rose. MK591 (blue sticks) is bound at 
membrane-embedded pockets of each 
monomer. Cytosolic (top) and nucleoplamic 
loops (bottom) may determine the 5-LO 
interaction site. 
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1.3.3  Role of FLAP in leukotriene biosynthesis 
Among the mammalian LOs, 5-LO is unique for the strong dependency on its helper-
protein FLAP in order to embrace full catalytic activity in intact cells. Intracellular Ca2+ 
release and subsequent phosphorylation redistributes 5-LO and cPLA2-α to the 
membranes (see 1.4). The nuclear membrane-embedded protein FLAP presents AA 
to 5-LO, and aides the initial step in LT biosynthesis by favoring the dehydration of 5-
HPETE to LTA4 [34]. So far, efficient substrate transfer as well as 5-LO activity support 
are the two known functions of FLAP. After AA is released, it is supposed to be bound 
by FLAP and subsequently handed over to 5-LO [107]. Genetic knockout of FLAP as 
well as pharmacological FLAP inhibition abolishes 5-LO product formation after 
stimulation [108]. In fact, exogenous supply of AA partially circumvents the need for 
FLAP as transfer protein in LT biosynthesis. Same effects were observed in 
osteosarcoma cells transiently expressing 5-LO but lacking FLAP [109]. Although 
these cell lines failed to produce LTs from endogenous sources, substantial amounts 
of 5-LO products were formed upon exogenous substrate supply. Of interest, co-
expression of FLAP in these cell lines improved the utilization of exogenous AA [2]. In 
consistence with these data, cell homogenates from human leukocytes or purified 5-
LO completely depend on exogenous substrate supply, and FLAP inhibitors lose their 
efficacy under these assay conditions.  
It is proposed that FLAP functions as a membrane anchor protein for 5-LO at the 
nuclear membrane after stimulation-induced translocation, and that FLAP inhibitors 
interfere with this translocation mechanism to prevent LT biosynthesis [110]. However, 
no convincing data for a protein-protein interaction of the native proteins in human 
leukocytes have been published so far. Although in vitro pull-down assays with artificial 
GST-tagged FLAP and 5-LO [111], or association studies using membrane-permanent 
cross-linking agents to perform fluorescence lifetime imaging microscopy (FLIM) in 
mouse neutrophils and rat RBL-2H3 cell lines [106] strongly suggest a direct 
interaction, the mode of association at the nuclear membrane is still vague. Moreover, 
pure co-localization studies with fluorescence microscopic techniques do not 
necessarily imply a physical protein-protein interaction.  
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1.4 Compartmentalization of LT biosynthesis 
The biosynthetic formation of LTs in the cell is strongly compartmentalized with 
enzymes distributed in the cytosol, extracellular space as well as nuclear membrane. 
This regulatory intracellular compartmentalization controls localization, catalytic 
activity and protein-protein interactions of key enzymes of the LT synthetic cascade. 
Thus, intervention with the subcellular localization of the enzymes/proteins offers an 
opportunity to prevent excessive LT biosynthesis. 
 
1.4.1  Subcellular localization of cPLA2-alpha 
The main substrate for 5-LO is AA, a polyunsaturated omega-6 fatty acid, 
predominantly found esterified in the nuclear membrane of cells [38]. The reacylation 
as well as the liberation rate limit the accessibility of free substrate for eicosanoid 
metabolism [112]. Among the known 15 PLA2 proteins, cPLA2-α is the only 
phospholipase that selectively cleaves AA in the sn-2 position of 1-palmitoyl-2-
arachidonoyl-sn-glycerophosphocholine from the nuclear membrane lipid bilayer [113]. 
Similar to 5-LO, cPLA2-α contains a N-terminal C2-like domain that binds Ca2+ and 
targets the enzyme to the AA-enriched perinuclear region, including the endoplasmic 
reticulum, Golgi apparatus, and nuclear envelope [114]. The C-terminal catalytic 
domain is distinct from other lipases and harbors an unusual Ser228/Asp549 dyad to 
control specificity for AA. The structure suggests a flexible lid that undergoes a 
conformational change after membrane binding in order to gain substrate access [115]. 
Besides Ca2+-binding, phosphorylation at Ser505 is sufficient to target the enzyme to 
the membrane, but maximal cPLA2-α activation involves both, as seen for 5-LO 
activation [114, 116]. Consequently, 5-LO and cPLA2-α act in a concerted manner upon 
cell activation and subcellular movement. The central role of cPLA2-α in AA metabolism 
is impressively demonstrated in cPLA2-α-deficient mice. Macrophages derived from 
these animals were not able to produce any eicosanoids and did not develop bronchial 
hyperreactivity in an anaphylaxis model upon stimulation [117]. 
 
 Introduction 
21 
 
 
Fig. 8: Structure of 
cytosolic phospholipase A2-
alpha.  cPLA2-α is rendered in 
cartoon (Protein Data Bank 
accession code, 1CJY). The N-
terminal C2-like domain is 
colored palegreen with two 
bound Ca2+ ions (yellow 
spheres). The mainly α-helical 
C-terminal catalytic domain is 
colored in blue, harboring the 
catalytic dyad Ser228 (pink) and 
Asp549 (purple). 
 
1.4.2  Subcellular localization of 5-LO  
Subcellular localization determines the fate of 5-LO activity and product formation. In 
unstimulated cells, 5-LO resides in the cytosol or nucleoplasm, depending on the cell 
type and cellular environment. While 5-LO is mostly cytosolic in primary neutrophils, 
peritoneal macrophages, differentiated HL-60, and Mono Mac 6 cells, 5-LO is equally 
distributed between cytosol und nucleus in primary monocytes, alveolar macrophages, 
mouse bone marrow-derived mast cells, rat basophilic leukemia cells, Langerhans 
cells of human skin, and in mast cells [50]. Interestingly, in 5-LO transfected cell lines 
e.g. COS, CHO, NIH 3T3 or in cancer cell lines like RAW macrophages, 5-LO is 
predominantly intranuclear [20]. 5-LO nuclear import depends on the NLS which 
appears to be regulated by phosphorylation. Phospho-Ser271 supports the nuclear 
import while phospho-Ser523 seems repressive [118, 119]. Site-directed mutagenesis 
of the NLS or/and respective regulation of respective phosphorylation sites significantly 
decreased LTB4 biosynthesis by 60–90%, which goes along with impaired intranuclear 
localization [80], and highlights the crucial role of 5-LO`s subcellular localization for 
activity.  
There is evidence that intranuclear 5-LO translocates mostly to the inner nuclear 
membrane, whereas cytosolic 5-LO traffics to the endoplasmic reticulum and outer 
nuclear membrane. Thus, the different membrane preference seems to determine the 
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fate of 5-LO downstream products with higher LTB4 levels of intranuclear 5-LO. The 
data are consistence with observations during adhesion and inflammation processes 
where 5-LO is directed from the cytosol to the intranuclear region of activated 
neutrophils [80]. On the other hand, targeting cytosolic 5-LO to the outer nuclear 
membrane appears to promote the formation of cys-LTs by LTC4S [106]. In contrast to 
LTC4S, FLAP is expressed in both, the inner and outer nuclear membrane. Two pools 
of FLAP have been identified: non-associated FLAP at both sides of the nuclear 
membrane, allowing nuclear soluble LTA4H to produce LTB4, and LTC4S-associated 
FLAP at the outer nuclear membrane [106]. Different interaction sites of FLAP with 5-
LO and LTC4S are predicted without a direct protein-protein interaction of 5-LO and 
LTC4S [106]. It is most likely that the FLAP/LTC4S interaction is necessary to channel 
the final 5-LO product LTA4 through the lipid bilayer from 5-LO to LTC4S via FLAP.  
Several studies suggest a multi-enzyme LT biosynthetic complex at the perinuclear 
region to achieve proper 5-LO activity and LT formation, involving cPLA2-α, FLAP, 5-
LO, CLP, and eventually LTC4S and LTA4H for further product metabolism [120]. FLIM 
analysis in mouse neutrophils already hypothesize a stimulation-dependent complex 
of 5-LO and FLAP, and a membrane association-mediated improved LTA4 formation 
[120]. The subcellular movement of 5-LO to the nuclear membrane requires a variety 
of stimulating factors like Ca2+-binding [121], and post-translational modifications like 
phosphorylation [71]. These activity regulating factors target 5-LO to the nuclear 
membrane, but FLAP is believed to anchor the protein at this locale [122]. Studies with 
FLAP inhibitors, competing for the AA-binding site, strongly suggest a regulating role 
of AA within this complex [94, 107]. Taken together, the knowledge about the complex 
mechanisms involved in substrate transfer and 5-LO/FLAP interaction is still vague. 
 
1.4.3  Downstream enzymes of the 5-LO pathway 
Depending on the expression of 5-LO downstream enzymes and 5-LO`s subcellular 
localization, 5-LO`s major product LTA4 can be converted by two separate pathways 
to the respective pro-inflammatory mediators [50]. LTA4 is either conjugated with 
reduced GSH by the nuclear membrane-embedded LTC4S to form cys-LTs or is regio-
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specific hydrolysed by soluble LTA4H to produce LTB4. These pro-inflammatory 
mediators can either be formed within one cell or by transcellular trafficking [123]. 
Like FLAP, LTC4S is a nuclear membrane protein and belongs to the MAPEG 
superfamily. There is some evidence for a biosynthetic functional complex of FLAP and 
LTC4S at the outer nuclear membrane [106]. Crystal structures are published for both 
proteins. The LTC4S structure was resolved in complex with GSH and a detergent-like 
mimic of LTA4 [124]. As seen for FLAP, the binding sites for GSH and LTA4 lie deep in 
a groove of the membrane bilayer. The deep substrate positioning requires lateral 
diffusion through the membrane as discussed for FLAP. Note that GSH slides deeper 
into the lipid bilayer than LTA4, and therefore is supposed to bind first and induce a 
conformational change for subsequent LTA4-binding [124]. However, an opposite 
binding mode is also possible and has not been precluded yet. Attack of the anionic 
thiol group of GSH on C-6 of the LTA4 epoxide ring yields the key compound of the cys-
LTs, the LTC4 [125, 126]. After metabolite export outside the cell successive cleavage 
of the glutamate and glycine residues lead to LTD4, and eventually LTE4. All three 
forming the group of cys-LTs. They act in nanomolar concentrations on G-protein 
coupled receptors, designated cysLT1 and cysLT2 [127]. While neutrophils lack LTC4S, 
high enzyme levels are present in monocytes, macrophages, mast cells, platelets and 
eosinophils [126, 128].              
An alternative fate for LTA4 is the LTA4H-mediated hydrolysis of the unstable epoxide 
ring to the chemoattractant mediator LTB4. In 2001, the crystal structure of the 
bifunctional (hydrolase and aminopeptidase activity) zinc-containing LTA4H was solved 
[129]. Human soluble LTA4H is expressed in neutrophils, monocytes, macrophages, 
lymphocytes, eosinophils and erythrocytes, whereas platelets and basophils lack the 
enzyme [130]. Besides the hydrolase function for LTB4 biosynthesis, the biological 
relevance of the aminopeptidase activity has not been fully determined yet. Recently, 
it was reported that the aminopeptidase activity cleaves the chemotactic tripeptide Pro-
Gly-Pro, and inactivation of this peptide appears to be beneficial in the resolution of 
inflammation [131, 132]. 
Besides these two pivotal downstream pathways, with LTA4 as the common substrate, 
the concerted catalytic actions during transcellular inflammatory response of 5-LO and 
15-LO (or 12-LO) lead to anti-inflammatory mediators like LX [23, 133].  
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2. AIM OF THESIS 
The overall aim of this thesis was to reveal the functionality and molecular basis for the 
assembly of the LT-biosynthetic 5-LO/FLAP complex at the nuclear membrane, and its 
pharmacological inhibition. The capacity of 5-LO to produce LTs from endogenous 
released AA is believed to be aided by FLAP [107]. Although FLAPs role in LT 
biosynthesis is known for more than three decades, the concerted action of FLAP with 
LT synthetic enzymes (e.g. 5-LO), and their complex assembly at the nuclear 
membrane are poorly understood. 5-LO product synthesis depends on a fine-tuned 
translocation process from a soluble compartment to the nuclear membrane-
embedded helper-protein FLAP. The mechanism of action however, are incompletely 
solved so far. It is challenging to understand how FLAP facilitates 5-LO activity, and if 
a direct protein-protein interaction occurs within this process. Genetic knock-out of 
FLAP [108] or inhibition [110] completely abolishes LT biosynthesis in vitro and in vivo, 
turning FLAP into a promising drug target for the treatment of LT-associated diseases. 
In the light of these facts, inhibition of FLAP instead of 5-LO appears to be the more 
valuable strategy. FLAP however, is an integral membrane protein devoid of enzymatic 
activity [4], excluding evaluations in cell-free assays.  
 
Specific objectives: 
1) Characterize the in vitro and in vivo pharmacology of the novel benzimidazole-
type FLAP inhibitor BRP-7 (manuscript I).  
2) Establish a suitable cell-based model stably expressing 5-LO and FLAP in 
HEK293 cells to determine putative FLAP inhibitors and investigate the role of 
FLAP for LT biosynthesis in cellulo (manuscript II). 
3) Study the influence of FLAP on 5-LO activity, metabolite profile, and subcellular 
localization of 5-LO (manuscript II).  
4) Determine the time-resolved in situ protein-protein interaction of native 5-LO 
and FLAP in human primary leukocytes and HEK293 cells in relation to 5-LO 
activity and 5-LO translocation (manuscript III). 
5) Identify modulating factors of the in situ assembly of 5-LO and FLAP at the 
nuclear membrane, and of its pharmacological inhibition (manuscript III).  
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3. MANUSCRIPTS 
 
Manuscript I 
Pergola, C., J. Gerstmeier, B. Monch, B. Caliskan, S. Luderer, C. Weinigel, D. Barz, J. 
Maczewsky, S. Pace, A. Rossi, L. Sautebin, E. Banoglu and O. Werz (2014). "The 
novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in 
vivo by targeting 5-lipoxygenase-activating protein (FLAP)." Br J Pharmacol 171(12): 
3051-3064. 
 
Manuscript II 
Gerstmeier, J., C. Weinigel, D. Barz, O. Werz and U. Garscha (2014). "An experimental 
cell-based model for studying the cell biology and molecular pharmacology of 5-
lipoxygenase-activating protein in leukotriene biosynthesis." Biochim. Biophys. Acta 
1840(9): 2961-2969. 
 
Manuscript III 
Gerstmeier, J., C. Weinigel, S. Rummler, O. Rådmark, O. Werz and U. Garscha (2015). 
"Time-resolved in situ assembly of the leukotriene-synthetic 5-LO / FLAP complex in 
blood leukocytes.” FASEB J, under review after invitation to submit. 
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3.1 Manuscript I 
 
The novel benzimidazole derivative BRP-7 inhibits leukotriene 
biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-
activating protein (FLAP) 
Pergola, C., J. Gerstmeier, B. Monch, B. Caliskan, S. Luderer, C. Weinigel, D. Barz, 
J. Maczewsky, S. Pace, A. Rossi, L. Sautebin, E. Banoglu and O. Werz (2014) 
British Journal of Pharmacology 171(12): 3051-3064. 
 
Here, we describe the in vitro and in vivo pharmacology of the novel and highly potent 
direct FLAP inhibitor BRP-7 [1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-
benzimidazole]. The benzimidazol derivative potently suppressed LT formation in 
primary intact human neutrophils (IC50 = 150 nM) and monocytes (IC50 = 40 nM), 
comcomitant with an impaired co-localization of 5-LO and FLAP. A reduced potency of 
BRP-7 to inhibit 5-LO product formation was observed in cell-free assays and upon 
ample supply of exogenous substrate. BRP-7 selectively bound to FLAP in pull-down 
assays, and did not interfere with other enzymes of the AA cascade like COX-1, mPGS-
1, and cPLA2-α. Finally, BRP-7 potently inhibited LT biosynthesis in HWB, and in a rat 
pleurisy and a mouse peritonitis model in vivo. Together, BRP-7 significantly abolishes 
5-LO activity by interference with FLAP and exhibits anti-inflammatory activity in vitro 
and in vivo, with promising potential for further development.  
 
 
Contribution (50%):   Cell culture and performance of blood cell isolation, 
purification of recombinant human 5-LO from E.coli, analysis of [3H]-AA release, 
evaluation of BRP-7 derivatives as FLAP inhibitors, HPLC analysis of 5-LO products, 
mPGS-1 assay, immunofluorescence microscopy of 5-LO in monocytes, analysis of 
data and preparation of graphs, analysis of statistics, co-writing of the manuscript.     
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3.2 Manuscript II 
 
An experimental cell-based model for studying the cell biology and 
molecular pharmacology of 5-lipoxygenase-activating protein in 
leukotriene biosynthesis 
Gerstmeier, J., C. Weinigel, D. Barz, O. Werz and U. Garscha (2014) 
Biochimica et Biophysica Acta 1840(9): 2961-2969. 
 
In this study, a smart cell-based model stably expressing 5-LO alone or together with 
FLAP in HEK293 cells was established to (I) characterize the 5-LO/FLAP interaction 
(II) and to screen for putative LT biosynthesis inhibitors. Co-expression of FLAP 
significantly increased LT biosynthesis by promoting the formation of LTA4. While FLAP 
inhibitors were only effective in intact cells co-expressing FLAP, direct 5-LO inhibitors 
did not distinguish between the two cell lines, and equally suppressed 5-LO product 
formation. All FLAP-mediated actions were abolished in cell homogenates, highlighting 
FLAP`s undisputed function for cellular LT biosynthesis. We conclude that FLAP 
stabilizes 5-LO at the nuclear membrane, and functions as a membrane anchor to 
promote efficient LTA4 biosynthesis at this locale. Together, we provide an innovative 
and powerful mammalian expression system to investigate the 5-LO/FLAP interaction 
and to evaluate novel FLAP antagonists. 
 
 
Contribution (80%):   Cloning of FLAP sequence into mammalian 
expression plasmid, stable transfection of HEK293 cells with pcDNA3.1/neom(+)_5-
LO and pcDNA3.1/hygro(-)_FLAP, purification of human leukocytes, 5-LO activity 
assays and inhibitor studies in HEK293 cells, monocytes, and neutrophils, HPLC 
analysis of 5-LO products, immunofluorescence microscopy, SDS-page and Western 
blot, [3H]-AA release, analysis of data and preparation of graphs, analysis of statistics, 
writing the manuscript.  
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3.3 Manuscript III 
 
Time-resolved in situ assembly of the leukotriene-synthetic 
 5-LO / FLAP complex in blood leukocytes 
Gerstmeier, J., C. Weinigel, S. Rummler, O. Rådmark, O. Werz and U. Garscha 
(2015) 
FASEB J, under review after invitation to submit. 
 
The assembly of 5-LO, FLAP, and CLP in activated human leukocytes at the nuclear 
membrane is pivotal for cellular LT biosynthesis. For the first time, we present the time-
resolved subcellular localization of these proteins, concomitant with LT biosynthesis, 
and provide distinct proof for the in situ protein-protein interaction of native 5-LO and 
FLAP in stimulated leukocytes, by proximity ligation assay. 5-LO/FLAP interaction 
occurs delayed compared to LT formation and 5-LO translocation, in contrast to the 
continuous, stimulus-independent 5-LO/CLP interaction. FLAP antagonists and 
inhibition of AA release abolished the 5-LO/FLAP assembly that was restored by 
exogenous AA and 5-HPETE without effecting 5-LO translocation and co-localization 
with FLAP. Though neutrophils and monocytes possess comparable quantities of 
catalytic active 5-LO enzyme, 5-LO activity in intact neutrophils is pronounced due to 
prolonged cellular 5-LO reaction, accompanied by delayed 5-LO nuclear membrane 
translocation. There is evidence that FLAP rather “regulates” cellular LT biosynthesis 
than simply “activates” it. 
 
 
 
Contribution (80%):   Purification of human monocytes and neutrophils, 5-
LO activity assay in intact cells and cell homogenates, HPLC analysis of 5-LO 
products, stable transfection of HEK293 cells, immunofluorescence microscopy, 
proximity ligation assay, [3H]-AA release, SDS-page and Western blot, data analysis 
and preparation of graphs, analysis of statistics, writing the manuscript.  
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4. DISCUSSION 
This thesis combines diverse experimental approaches to define the molecular basis 
for the complex assembly of 5-LO and FLAP in intact cells to produce LTs, and its 
pharmacological inhibition. LTs are potent lipid mediators in the pathological 
development of diseases like asthma, rhinitis, cancer, and CVD [3]. Upon cell 
activation, endogenous released AA is converted by 5-LO in a two-step reaction that 
proceeds via the intermediate 5-HPETE (dioxygenase activity) to LTA4 (epoxidase 
activity) [12]. In contrast to a cell-free environment, the fate of 5-LO to be catalytic 
active in cellulo is strongly controlled by compartmentalization with enzymes in the 
cytosol, nuclear membrane, and extracellular space. The compartmentalized 
biosynthetic LT pathway offers opportunities to abate inflammatory responses through 
the dynamic control of the subcellular localization of 5-LO as key enzyme for LT 
biosynthesis. A fine-tuned regulatory machinery ascertains 5-LO activity, stability, 
localization, and protein-protein interactions, as well as 5-LO self-inactivation. Cellular 
5-LO catalysis depends on an essential translocation process from the cytosol or 
intranuclear region to the nuclear membrane-bound FLAP upon activation [2]. 5-LO 
activity and access to the LT precursor AA is believed to be aided by FLAP [107]. It is 
assumed that FLAP acts as a scaffold for 5-LO that ascertains the association of 5-LO 
at the perinuclear region to enable efficient LTA4 formation at this locale [34]. FLAP has 
been shown to bind AA as well as certain other fatty acids [107] but how FLAP transfers 
the substrate to 5-LO for efficient metabolism, facilitates 5-LO catalytic activity, and 
whether an interaction between the two proteins is required remain unanswered 
questions to date. It has still not been defined what happens throughout the catalytic 
cycle of 5-LO at the nuclear membrane These are important questions to address as 
FLAP was shown to determine the subcellular localization of 5-LO, and thus its 
capacity to produce LTs. Lack of FLAP or pharmacological inhibition in cellulo or in vivo 
completely prevents LT formation from endogenous sources of AA [4], and FLAP 
antagonists were reported to intervene with the essential 5-LO translocation to the 
perinuclear region [59, 110]. Thus, it is not surprising that the pharmacological 
development of compounds targeting FLAP instead of 5-LO to reduce LT biosynthesis 
has been constantly increased since the discovery of FLAP. Antagonists of FLAP were 
shown to be promising drug candidates for the treatment of inflammatory and allergic 
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diseases by interference with the 5-LO pathway [4], and to be highly beneficial in the 
treatment of CVD [21]. An additional exceptional advantage of blocking FLAP instead 
of 5-LO, is the recently discovered involvement of cytosolic 5-LO for the formation of 
pro-resolving LXA4 [134]. Cytosolic localization of 5-LO is believed to be regulated by 
FLAP expression and its antagonists. Compounds targeting FLAP like MK886, MK591 
or BAY X-1005 are highly efficient in limiting cellular 5-LO product formation from 
endogenous AA [91], but are less potent in vivo and eventually failed in clinical trials, 
Recent developments like GSK2190915 [99] solely concentrate on the classical FLAP 
inhibitor type MK886, whereas novel structures are rare.       
 
4.1 Pharmacological characterization of the novel 
FLAP antagonist BRP-7 
Encouraged by the therapeutic potential of FLAP as promising drug target, a novel 
chemotype for FLAP inhibitors was recently discovered by us in a virtual screening 
approach based on a combined ligand- and structure-based pharmacophore model 
(Fig. 9) [5].  
Fig. 9: Ligand- and structure-based 
pharmocophore model reveals 
novel chemotype for FLAP 
inhibitors. (Right) Pharmacophore 
model consists of three aromatic rings, 
three hydrophobobic features and the 
respective spatial arrangement. (Left) 
Chemical structure of BRP-7. 
 
 
The innovative compound BRP-7 [1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl)ethyl)-1H-
benzimidazole] potently prevented 5-LO activity in intact human leukocytes but failed 
to directly inhibit 5-LO, suggesting FLAP inhibition as mode of action. The structural 
key element of BRP-7 is a non-acidic benzimidazole scaffold with an 
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isobutylphenylethyl ibuprofen fingerprint. This is in sharp contrast to the well-
established quinoline- (BAY X-1005) or indole-based (MK886) FLAP inhibitors that 
both contain a carboxylic acid group, and strongly differ in the overall structure. Thus, 
BRP-7 is an excellent candidate for further developments of novel innovative FLAP 
antagonists. Unlike others, BRP-7 not only prevented LT biosynthesis in vitro, but was 
also effective in vivo. BRP-7s pharmacology was intensively studied within the frame 
of this thesis and revealed (I) significant cellular inhibition of 5-LO activity in isolated 
primary human neutrophils (IC50: 150 nM) and monocytes (IC50: 40 nM) (II) without 
direct inhibition of 5-LO, (III) interference with 5-LO translocation to the nuclear 
membrane, (IV) specific inhibition of FLAP without side effects on other enzymes of 
the AA cascade, (V) no inhibition of CYP3A4 or hERG, and (VI) reduced LT 
biosynthesis in HWB assays, and in vivo animal models of acute inflammation. 
Together, the results provide strong evidence that the pharmacological target of BRP-
7 is FLAP.  
The compound exhibits typical properties of well-characterized FLAP inhibitors, that is, 
high cellular efficacy and poor inhibition of LTs in cell-free assays like cell homogenates 
or isolated recombinant 5-LO [135]. Up to 100-times higher concentrations of BRP-7 
are required to inhibit 5-LO product synthesis under cell-free conditions which is similar 
to the pharmacology of MK886. Of interest, non-redox type 5-LO inhibitors act similar 
in cell-free assays due to a lack of reducing agents (e.g. GSH) [47]. However, BRP-7 
did not inhibit 5-LO activity in leukocyte homogenates upon supplementation with GSH, 
which excludes a function as non-redox type 5-LO inhibitor but supports the hypothesis 
of FLAP as cellular target for BRP-7. Exogenous substrate supply has been shown to 
evade FLAP as AA transfer protein [4]. As expected, high excess of free AA to A23187-
stimulated intact leukocytes abated BRP-7`s potency in a concentration-dependent 
manner. Seemingly, BRP-7 competes with AA for the binding to FLAP as reported 
before for other FLAP antagonist [100].  
To confirm FLAP as the proposed target, the compound was coupled to an affinity 
matrix and isolated nuclear membranes from human neutrophils were used as sources 
of FLAP for in vitro pull-down assays. Indeed, FLAP was enriched in pull-downs of 
matrix-coupled BRP-7 which was competitively abolished by high excess of soluble 
BRP-7. In sharp contrast to MK886, no intervention with other AA-metabolizing 
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enzymes like COX-1, 12- or 15-LO, and mPGES-1 or AA-releasing cPLA2-α was 
evident, confirming BRP-7s high selectivity for FLAP.  
Although FLAP inhibitors were reported to impair the translocation of soluble 5-LO to 
the nuclear membrane for the association with FLAP [79], only high concentrations of 
BRP-7 marginally reduced the 5-LO/FLAP co-localization. This indicates that LT 
suppression by BRP-7 is not directly related to an impaired 5-LO translocation and co-
localization with FLAP. Interestingly, BRP-7 reduced LT biosynthesis more prominent 
in monocytes (IC50: 40 nM) than in neutrophils (IC50: 150 nM), which might be related 
to diverse functional relevancies of FLAP for cellular LT biosynthesis in neutrophils 
versus monocytes.  
Unlike other FLAP inhibitors, BRP-7 remained highly effective in HWB assays and two 
well-established in vivo animal models of acute inflammation: carrageenan-induced 
pleurisy in rats and zymosan-induced peritonitis in mice [104]. A major drawback of 
previous FLAP inhibitor studies has been their strong interference with CYP enzymes 
[123], but no significant inhibition of CYP3A4 by BRP-7 was evident. Also, neither 
hERG inhibition nor toxic effects on cell integrity and viability were observed for BRP-
7-treated mice and rats. Together, the detailed in vitro and in vivo study of BRP-7 
suggests FLAP as its pharmacological target, and excludes direct inhibition of 5-LO, 
cPLA2-α or other AA-metabolizing enzymes. However, no straight forward and smart 
model was available at this time to determine a direct functional interference of BRP-7 
with FLAP. Certainly, it is challenging to study the functionality of FLAP and its 
relevance for LT biosynthesis as FLAP is devoid of enzymatic activity and the 5-
LO/FLAP interaction is limited to the cellular context. Also, FLAP is an integral 
membrane protein that needs a bilayer surrounding to express full functionality, limiting 
studies with the purified protein [125].  
To date, putative antagonist of FLAP have been evaluated for their efficiency to 
suppress 5-LO activity solely in intact cells but failed to inhibit in cell-free assays as 
discussed for BRP-7, or radioactive-labelled inhibitor analogues were used to 
determine their binding affinity towards FLAP from nuclear membrane preparations of 
human leukocytes [95]. For this assay however, competitive binding of the inhibitor 
with AA to FLAP is essential, whereas allosteric regulators cannot be distinguished. 
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Major drawbacks of previous attempts to establish a cell-based model to identify 
putative FLAP antagonists and investigate the assembly of the LT biosynthetic complex 
at the nuclear membrane in mammalian cells were the use of (I) transiently expression 
systems [2, 122] and (II) artificial (cell-free) GFP- or GST-tagged 5-LO or FLAP fusion 
proteins [136] that eventually interfere with the biological relevance and reproducibility 
of the experiments. However, there is strong need for an improved knowledge about 
the assembly of the 5-LO/FLAP interaction as a better understanding of this 
biosynthetic complex at the nuclear membrane and its functionality will help to develop 
novel potent FLAP inhibitors with multi-points of attack, and expedite pharmacological 
intervention strategies for improved therapeutic approaches in LT-associated diseases.  
 
4.2 FLAP promotes cellular LTA4 synthase activity 
of 5-LO  
The molecular and mechanistic basis of the 5-LO/FLAP interaction has been elusive 
as FLAP modulates 5-LO activity only at the cellular level and could not yet be 
recapitulated in vitro.Thus, the next key step of this thesis was the development of an 
experimental cell-based system to study the in cellulo 5-LO/FLAP interaction, elucidate 
FLAP´s functionality in LT biosynthesis, and establish a suitable tool to screen for novel 
FLAP inhibitors. In brief, HEK293 were stably transfected with 5-LO alone (HEK-5-LO) 
or together with FLAP (HEK-5-LO/FLAP). Unlike previous studies with isolated human 
primary leukocytes or mammalian cell lines that express endogenous 5-LO and FLAP, 
the HEK293 cell system allows to obtain deeper insights into the assembly of the 
putative 5-LO/FLAP complex for example by considering site-directed mutagenesis 
experiments. Promising residues for future investigations in helix α2 of human 5-LO 
are Phe177 and Tyr181, often referred to as the “FY-cork”, that appear to control the 
entrance of AA to 5-LO`s active site [27], or deletions of residues within the two 
cytosolic loops of FLAP that are exposed to the membrane, and thus regions most 
likely to interact with 5-LO [100]. Equal expression levels of FLAP and 5-LO in the 
HEK293 cells were verified by immunoblotting. 5-LO product formation was analyzed 
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by HPLC in intact cells versus cell homogenates, and the subcellular localization of the 
proteins was determined by IF microscopy.  
Both cell lines efficiently metabolized exogenous AA upon stimulation with the Ca2+-
mobilizing agent A23187. Detectable 5-LO products comprised 5-H(p)ETE and the 
trans-isomers of LTB4. As FLAP is supposed to function as a transfer protein for 
endogenously released AA to 5-LO [107], we expected significant amounts of LTs upon 
activation by A23187 without supply of exogenous substrate in cells co-expressing 
FLAP. Unexpectedly, no detectable amounts of 5-LO products (<2 ng/106 cells) in HEK-
5-LO/FLAP as well as HEK-5-LO cells were observed after stimulation with A23187 for 
10 min at 37 °C. Control experiments with primary human neutrophils and monocytes 
under equal assay conditions led to significant amounts of LTs as reported before [17, 
83]. Moreover, a stable cell line expressing platelet-type 12-LO (HEK-12-LO) 
generated 12-H(p)ETE after activation by A23187, which is in sharp contrast to 5-LO 
expressing cells, regardless of FLAP. 12-H(p)ETE was consistently produced for more 
than 15 min after an unusual lag phase of about 2 min. In human platelets however, 
12-LO metabolizes endogenous released AA within seconds upon stimulation [102] 
which indicates an impaired AA release in HEK293 cells compared to primary blood 
cells. Although 5-LO in cells with and without FLAP failed to produce LTs from 
endogenous sources of AA, the addition of 3, 10 or 30 µM AA to A23187-stimulated 
cells led to significant amounts of 5-LO products, superior to those observed in human 
primary monocytes and neutrophils in parallel experiments.  
The unusual lag phase in HEK-12-LO cells to form AA-derived products and the low 
LT formation from endogenous AA in 5-LO and FLAP co-expressing cells prompted us 
to investigate the cPLA2-α-mediated AA hydrolysis from phospholipids within the 
membrane. Potentially, cPLA2-α is not as functional active in HEK293 cells as it is in 
human leukocytes to evoke the complex assembly of 5-LO and FLAP. However, 
3[H]AA-labelled HEK293 cells released significant amounts of AA-derived products 
upon activation with A23187 that could be inhibited by the specific cPLA2-α inhibitor 
RSC-3388. These results preclude an absolute lack of liberated endogenous AA in 
A23187-stimulated HEK293 cells. Compared to human neutrophils and monocytes 
however, the relative amount of liberated AA in HEK293 cells was rather weak and 
delayed, most likely insufficient to enable the complex assembly of 5-LO and FLAP at 
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the nuclear membrane but appears to be sufficient for cytosolic 12-LO activity (HEK-
12-LO). Also, we cannot exclude that in HEK293 cells AA gets liberated from other lipid 
sources than the nuclear membrane, as cPLA2-α has been shown to translocate also 
to the endoplasmic reticulum, as well as Golgi apparatus [113]. In fact, AA release from 
these membranes might be accessible for cytosolic 12-LO but not for nuclear 
membrane-associated 5-LO. Finally, the content of phospholipids containing sufficient 
AA in sn-2 position may be limited in HEK293 cell cultures versus primary neutrophils 
or monocytes. 
It appeared possible that 5-LO/FLAP co-localization upon translocation of soluble 5-
LO is not operative in the HEK cell lines. Thus, the subcellular localization of 5-LO and 
FLAP in resting and activated cells was analyzed by IF microscopy. Unstimulated cells 
revealed a rather homogenous distribution of soluble 5-LO in the nucleus and in the 
cytosol. In cells lacking FLAP, 5-LO essentially redistributed in the intranuclear region 
without marked nuclear membrane association upon stimulation. This is in sharp 
contrast to FLAP co-expressing cells. Here, soluble 5-LO translocated to the nuclear 
membrane, harbouring FLAP. Both proteins clearly co-localized at this locale. This co-
localization was impaired by high concentrations of the FLAP antagonist MK886 (300 
nM), which is in agreement with reported MK886 properties in human leukocytes [110]. 
The subcellular localization of 5-LO in MK886-treated HEK-5-LO/FLAP cells 
resembled a similar pattern observed in A23187-activated cells lacking FLAP.  
An improved membrane binding of 5-LO is considered to promote LTA4 biosynthesis 
[29], but how FLAP facilitates the efficient metabolism of AA remained elusive. In fact, 
FLAP co-expression significantly promoted the conversion of exogenous AA to 
increased levels of LTA4 compared to cells lacking FLAP. In particular, the formation of 
LTA4 at 3 µM AA, resembling the physiological concentration of liberated AA of A23187-
stimulated primary human leukocytes [103], was significantly pronounced in HEK-5-
LO/FLAP cells. The ratio of 5-H(p)ETE versus trans-isomers of LTB4 was markedly 
reduced from 6:1 in HEK-5-LO to 2:1 in HEK-5-LO/FLAP cells. The observed FLAP-
mediated effect was blocked by MK886 in a concentration-dependent manner. This is 
of interest as MK886 was shown to compete with AA for the binding pocket in FLAP 
[95]. Under conditions where FLAP supported 5-LO activity, MK886 reduced LT 
biosynthesis by 35% at low nanomolar concentrations. In fact, predominantly the 
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formation of LTA4 was blocked by MK886, and thus the described 5-LO-stimulatory 
effect of FLAP. No similar observations were made for the direct 5-LO inhibitor zileuton. 
As expected, MK886 did not reduce LT biosynthesis in intact HEK-5-LO cells lacking 
FLAP, and was ineffective in homogenate preparations of both cell lines independently 
of FLAP expression. Note that FLAP is dispensable for 5-LO activity under cell-free 
assay conditions [137]. The direct 5-LO inhibitor zileuton however, equally inhibited 5-
LO activity in intact cells and homogenates, regardless of the presence of FLAP. As 
described before for several FLAP inhibitor studies in human leukocytes including 
BRP-7, substantial amounts of exogenous AA (e.g. 30 µM) circumvent the necessity 
of FLAP as substrate transfer protein for 5-LO in intact cells [138], and all described 
unique characteristic of FLAP co-expressing cells were vanished. No significant 
increase of 5-LO activity nor differences in the formed metabolite profile were 
determined for both cell lines. Together, our results highlight FLAPs central role as 5-
LO-stimulating protein in intact cells for in situ LT biosynthesis. 
Fig. 10: FLAP controls the 
conversion of AA to LTA4. 5-
HPETE formation from AA by 5-LO 
appears to be largely independent 
of FLAP co-expression, whereas 
efficient LTA4 formation is prompted 
in the presence of FLAP. 
 
 
 
 
To date, FLAP has been known to function as a transfer protein for endogenous 
released AA, possibly anchoring 5-LO to the nuclear membrane for substrate 
acquisition [34, 139]. Our data provide strong evidence that FLAP not only transfers 
AA to 5-LO but also positions the intermediate 5-HPETE at the active site to assure 
efficient LTA4 formation. Hence, we expose an additional function of FLAP, that is, 
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support of the LTA4 synthase activity of 5-LO without marked effects on the 5-HETE 
production (Fig. 10).  
The established HEK293 cell model is a suitable tool to study the role of FLAP for 5-
LO catalysis, and to distinguish putative FLAP antagonists from interference with 5-
LO. In fact, FLAP inhibitors are highly beneficial for the treatment of LT-associated 
diseases in current clinical trials [134], and the described cellular model may contribute 
to identify highly potent FLAP antagonists in early preclinical studies. Although FLAP 
and 5-LO co-localized at the nuclear membrane, and endogenous AA was liberated by 
cPLA2-α, no 5-LO products were detectable. Upon exogenous supply of AA however, 
LT biosynthesis was significantly increased in the presence of FLAP. In conclusion, 
other enzymes of the AA cascade like cPLA2-α, LTC4S and/or LTA4H might be involved 
in the assembly of the fine-tuned LT biosynthetic complex, which is functional in 
primary human cells but not completely operative in the established cell model. Hence, 
further studies in primary cells appear necessary for a complete understanding of the 
fine-tuned machinery of the 5-LO/FLAP pathway. 
 
4.3 Time-resolved in situ interaction of native 5-LO 
and FLAP  
Biochemical and IF microscopy data clearly pointed out a strong need for 5-LO to 
translocate to the nuclear membrane-embedded FLAP in intact cells in order to gain 
full activity, but do they really physically interact? Questions regarding the often 
proposed interaction between 5-LO and FLAP for cellular LT biosynthesis remain 
unanswered, and if additional factors regulate this interaction in intact human primary 
cells could not be addressed with the established HEK293 cell model described above. 
Previous attempts to reveal the mechanism for the tight assembly of the 5-LO/FLAP 
complex at the nuclear membrane were rather unsatisfying. Major drawbacks of 
previous studies were the use of artificial fusion-proteins instead of native 5-LO and 
FLAP in other species than human. Despite in vitro pull-down assays and co-
immunoprecipitation experiments with GST-tagged 5-LO and FLAP [106, 111], or GFP-
based fluorescence lifetime imaging microscopy (FLIM) analysis for association 
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studies upon enforced protein cross-linking [106], no persuasive proof for a direct and 
effective interaction of native 5-LO and FLAP in primary human leukocytes has been 
provided, until now. Moreover, the subcellular co-localization of two proteins, visualized 
by IF microscopy, does not necessarily imply a tight and functional active protein-
protein interaction.  
For the first time, we determined the time-resolved subcellular localization of 5-LO, 
concomitant with LT biosynthesis, and provide strong evidence for an effective in situ 
interaction of native 5-LO and FLAP at the nuclear membrane in A23187-activated 
primary human leukocytes and stable transfected HEK293 cells by proximity ligation 
assay (PLA). What is particular attractive regarding this sophisticated method is the 
possibility to detect in situ protein-protein interactions of unmodified, native proteins 
(no tags, dyes, or labels) at a defined cellular locale [6]. A PLA signal is detectable by 
fluorescence microscopy if the two proteins of interest are in close proximity with a 
distance < 40 nm. 
Among all 5-LO and FLAP expressing mature myeloid cells [30], monocytes and 
neutrophils possess the highest capacity to generate LTs [140, 141]. At first, we 
compared the amounts of produced LTs from both cell types in intact cells and 
homogenates upon stimulation. Interestingly, intact neutrophils metabolized 3 to 5-
times higher 5-LO products versus intact monocytes, but followed a similar kinetic 
course in crude cell homogenates with equivalent levels of produced LTs. This implies 
a similar catalytic active 5-LO in both cell types per se. Note that 5-LO activity after cell 
homogenization is mostly independent of cell type-specific regulation [137], and FLAP 
supports 5-LO activity solely in cellulo [34]. This was already demonstrated in the 
HEK293 cell model and pharmacological study of BRP-7. In line with these findings, 
equal protein expression levels of 5-LO in neutrophils and monocytes were verified by 
Western Blot, normalized to actin. The expression level of FLAP however, was 
significantly lower in monocytes. This is of interest as FLAP is supposed to facilitate 
the transfer of endogenously released AA to 5-LO [107]. It is tempting to consider the 
higher expression level of FLAP in neutrophils as reason for the improved product 
formation. Also, it appeared possible that the observed differences in LT biosynthesis 
may also result from an enhanced AA liberation by cPLA2-α. Indeed, A23187-
stimulated neutrophils released significantly higher amounts of AA and its metabolites 
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from [3H]AA-labelled neutrophils compared to monocytes which could be blocked by 
the cPLA2-α inhibitor RSC-3388. To avoid cell-type specific discrepancies in the cPLA2-
α activity, increasing concentrations of exogenous AA (3, 10 or 30 µM) were added to 
A23187-stimulated neutrophils and monocytes.To our surprise, LT biosynthesis was 
again 3- to 5-times more pronounced in neutrophils versus monocytes, independent of 
exogenous substrate supply. Consequently, the superior 5-LO product formation in 
neutrophils cannot simply be explained by an improved AA liberation rate which 
prompted us to analyse the LT biosynthesis from endogenous sources of AA in a time-
dependent manner. Indeed, a rather delayed and significantly prolonged 5-LO activity 
in neutrophils compared to monocytes was observed. While LT biosynthesis in 
monocytes was essentially completed 60-90 sec post stimulation without significant 
differences in the kinetic course of 5-LO product formation in neutrophils at this time, 
5-LO catalysis in neutrophils continued up to 180 sec, resulting in higher levels of LTs. 
Nevertheless, the impact of a more physiological relevant stimulus like LPS plus fMLP 
or PAF should be addressed in future studies as the immediate and receptor-
independent Ca2+ ion influx in A23187-stimulated cells circumvents complex signalling 
pathways that may account for cell-type specific regulation of 5-LO in monocytes and 
neutrophils [121].  
As discussed above, 5-LO catalysis depends on an essential translocation process 
during activation to establish the LTA4-biosynthetic complex with FLAP at the nuclear 
envelope. Therefore, we monitored the time-dependent subcellular localization of 5-
LO and FLAP by IF microscopy. This is in sharp contrast to previous studies that 
determined the 5-LO/FLAP co-localization solely after one fixed time-point (10 or 30 
min) post stimulation [106, 120]. Our kinetic analysis of LT biosynthesis however, 
indicated a limited period of active 5-LO within the first 3 min upon activation. Again, 5-
LO nuclear membrane association and co-localization with FLAP was more rapid in 
monocytes compared to neutrophils, and appeared earliest at 60-90 sec upon 
stimulation without alterations up to 30 min. In line with prolonged LT biosynthesis in 
neutrophils, 5-LO translocation occurred delayed and continued up to 180 sec. Thus, 
5-LO translocation strongly correlated with the time periods for 5-LO product formation. 
In conclusion, 5-LO catalysis occurs as long as a pool of soluble 5-LO traffics to the 
nuclear membrane-bound FLAP for substrate acquisition and turn-over. In the cell, 5-
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LO activity appears to be terminated by membrane and/or FLAP association, leading 
to irreversible turnover-based suicide inactivation of 5-LO [89, 90]. Similar observations 
were made for purified 5-LO in the presence of AA and PC vesicles. The rate of 
inactivation primarily depends on substrate accessibility and concentration, as well as 
lipid peroxides within the phospholipid membrane [88], eventually terminating 5-LO 
product synthesis by non-turnover inactivation. Together, the data indicate that 
enhanced LT biosynthesis in neutrophils is a result of a prolonged translocation pool 
of active 5-LO. How membrane and/or FLAP association however, leads to 5-LO 
inactivation remained elusive. IF microscopy of 5-LO and FLAP allowed only 
predictions about their co-localization at a defined locale without proof for a direct and 
physical protein-protein interaction.  
To investigate the tight assembly of 5-LO and FLAP, a novel technique for the detection 
of direct protein-protein interactions was applied, the PLA. Unlike GFP-based FRET 
approaches, PLA probes capture the interacting proteins in their native form (Fig. 11). 
This is especially important for the 5-LO/FLAP interaction, which may be transient with 
a lifetime of a single catalytic cycle. 
 
Fig. 11: Principle of in situ PLA. Cells were incubated with primary antibodies against 5-LO (mouse) 
and FLAP (rabbit), incubated with PLA probes anti-mouse PLUS and anti-rabbit MINUS, ligated to a 
closed circle < 40 nm proximity, followed by amplification and fluorophore hybridization (magenta dots). 
 
As expected, 5-LO and FLAP do not interact in resting cells due to different distributions 
in the cell. Upon A23187-stimulation, 5-LO traffics to the nuclear membrane harbouring 
FLAP, and a clear PLA signal illustrating the 5-LO/FLAP interaction was detected in 
human primary leukocytes as well as stable transfected HEK293 cells. Note that the 
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PLA signal appeared earliest around 90 sec in monocytes and not until 3 min post 
stimulation in neutrophils, time-points where LT biosynthesis and 5-LO translocation 
was already completed. Interestingly, the signal increased up to 30 min post activation 
in both cell-types. We are aware of the possibility that AA may be required for such an 
interaction, and speculate that 5-LO first loosely associates with FLAP upon 
translocation for substrate acquisition and turn-over before a tight interaction occurs. 
As long as LT biosynthesis proceeds, both proteins are not yet within the distance for 
ligation of the PLA probes. Consequently, the 5-LO/FLAP interaction occurs delayed 
compared to 5-LO translocation and product formation. The data indicate that FLAP 
not simply functions as membrane anchor for 5-LO but also brings the enzyme in a 
resting mode upon completed catalytic cycle to temper LT biosynthesis. 
In sharp contrast to the stimulation-dependent 5-LO/FLAP assembly, 5-LO interacts 
permanently and independent of stimuli with its scaffold CLP, which was determined 
before by co-IP [59]. Monitoring the 5-LO/CLP interaction resulted in a strong PLA 
signal without time-related discrepancies in monocytes and neutrophils. Although 
previous studies suggested a pronounced association of CLP with 5-LO upon Ca2+-
binding [33, 59], the PLA signal did not increase upon A23187-mediated Ca2+ influx. 
However, a Ca2+-dependent binding mode might not be detectable by PLA but could 
influence the extent of co-IP experiments.  
To further validate and characterize the 5-LO/FLAP assembly, HEK293 cells stably 
expressing 5-LO with or without FLAP were analyzed. As expected, PLA signals were 
only evident in A23187-stimulated FLAP co-expressing cells. Second, when HEK293 
cells were transfected with the 5-LO_3W mutant (Trp13/75/102Ala), unable to associate 
with the nuclear membrane and co-localize with FLAP in IF experiments, no PLA signal 
was detected independent of stimulation and FLAP co-expression. An abolished 
binding to PC [41] and/or CLP by the 5-LO_3W mutant [33] is most likely the reason 
for the observed insufficient translocation process and association with FLAP.  
Finally, FLAP inhibitors are known to compete with AA for the binding site at FLAP, and 
to interfere with FLAP`s function as transfer protein for AA to activated and membrane-
associated 5-LO which prompted us to investigate the influence of two structural 
unrelated FLAP inhibitors MK886 [110] and BAY X-1005 [92] on the assembly of 5-LO 
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and FLAP. Both FLAP antagonists did not impair the 5-LO translocation and co-
localization with FLAP, but the PLA signal was clearly abolished upon inhibitor 
treatment prior stimulation. The direct 5-LO inhibitor zileuton [142] did not influence the 
5-LO/FLAP co-localization and interaction. Consequently, future inhibitor studies need 
to distinguish between 5-LO/FLAP co-localization and 5-LO/FLAP interaction.  
In the HEK293 cell model FLAP not only promoted substrate acquisition and 
conversion of AA to 5-HPETE but also the dehydration of 5-HPETE to LTA4. To 
investigate the regulating function of AA and 5-HPETE for the 5-LO/FLAP interaction, 
AA release was inhibited by the cPLA2-α inhibitor RSC-3388 prior stimulation. Again 
the assembly of the 5-LO/FLAP complex was reduced, whereas 5-LO translocation 
and co-localization with FLAP was not affected as reported by others before [120]. Of 
interest, exogenous supply of AA (10 µM) and 5-HPETE (5 µM) restored the complex 
assembly. Thus, we confirmed that AA and/or 5-HPETE possess a regulating function 
for the observed interaction or might induce a conformational shift of FLAP ready to 
interact with 5-LO. Together, competitive inhibition of AA-binding to FLAP as well as 
blockade of AA release prevented the interaction of 5-LO and FLAP at the nuclear 
membrane of activated leukocytes and HEK-5-LO/FLAP cells.  
The results of this thesis highlight FLAPs role as transfer protein for AA, and support 
FLAPs function for 5-HPETE transfer and/or retention at 5-LOs active site to produce 
LTA4. In addition to the effects of AA in our experiments, the prevention of the LTA4-
biosynthetic 5-LO/FLAP complex by FLAP inhibitors strengthens the biological 
relevance of our findings. We emphasize that 5-LO translocation is independent of 
FLAP expression or inhibition, and endogenous substrate supply by cPLA2-α which is 
in line with an unimpaired 5-LO translocation to the perinuclear region in HEK-5-LO 
cells lacking FLAP. Finally, FLAP appears to be more than purely an “activating” protein 
for 5-LO catalysis during inflammation. The study contributes to a better understanding 
of the role of FLAP as regulating protein for 5-LO activity and LT biosynthesis. FLAP 
not simply functions as a membrane anchor for 5-LO, it appears to generate a time-
dependent assembly of a loose LTA4-biosynthetic 5-LO/FLAP complex at the nuclear 
membrane. At first, FLAP enables and regulates LT formation in order to eventually 
temper the pro-inflammatory response by retaining 5-LO at the nuclear membrane 
within a tight complex. It is shown for the first time that the subcellular 
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compartmentalization of 5-LO, the efficacy and extend to produce LTs, is highly 
dependent on the presence of the nuclear membrane-embedded 5-LO helper-protein 
FLAP (Fig. 12). The improved knowledge and established assays may help to develop 
and characterize innovative FLAP inhibitors, and expedite novel pharmacological 
intervention strategies for LT-associated diseases.  
 
Fig. 12: The complex orchestra of LT biosynthesis in the cell. 5-LO, associated with CLP, 
translocates to the nuclear membrane upon stimulation. AA is released by cPLA2-α, and transferred via 
FLAP to 5-LO for LTA4 biosynthesis. AA and 5-HPETE regulate the assembly of 5-LO/FLAP complexes. 
Two populations of 5-LO/FLAP complexes are assumed to control the fate of LTA4. Complexes at the 
outer nuclear membrane appear to be dedicated to LTC4 formation by LTC4S, while complexes at the 
inner membrane pronounce LTB4 biosynthesis by LTA4H.  
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